Literature DB >> 3880685

Dynamic responses to intravenous urapidil and dihydralazine in normal subjects.

G G Belz, J H Matthews, D Graf, H C Stern, R Bachmann, G Belz, V W Steinijans, D Palm.   

Abstract

Hemodynamic responses after urapidil were compared with those after dihydralazine in placebo-controlled, double-blind studies after cumulative intravenous doses. We recorded heart rate, blood pressure, systolic time intervals corrected for heart rate (electromechanical systole and preejection period), electrical impedance cardiography [(dZ/dt)/RZ index and mean electrical thorax impedance], and M-mode echocardiogram (end-systolic and -diastolic diameters, end-systolic wall stress, fractional shortening, and cardiac output). Both drugs induced dose-dependent reductions in total peripheral resistance, which resulted in reduction in left ventricular end-systolic wall stress and increases in heart rate (limited at +10 bpm with urapidil), fractional shortening, cardiac output, and the (dZ/dt)/RZ index. With each drug, diastolic blood pressure fell by 5 mm Hg, the corrected preejection period shortened (dihydralazine greater than urapidil), the corrected electromechanical systole did not change, and mean electrical thorax impedance rose with urapidil. The spectrum of effects indicates that both drugs reduce left ventricular afterload, thereby increasing left ventricular pump performance. Urapidil also exerts some preload reduction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3880685     DOI: 10.1038/clpt.1985.10

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Differential cardiovascular effects of propranolol, atenolol, and pindolol measured by impedance cardiography.

Authors:  S H Thomas; R C Cooper; M Ekwuru; S Fletcher; J Gilbody; T S Husseyin; M Ishaque; R Jagathesan; G Reddy; S E Smith
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Renal haemodynamic and neurohumoral responses to urapidil in hypertensive man.

Authors:  P W de Leeuw; P N van Es; H A de Bruyn; W H Birkenhäger
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  The effect of urapidil on responses to phenylephrine, angiotensin and isoprenaline in man.

Authors:  B Tomlinson; J C Renondin; B R Graham; B N Prichard
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Systolic time intervals in clinical pharmacology.

Authors:  Q Li; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Human pharmacology of urapidil.

Authors:  A M Shepherd
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  Haemodynamic effects of urapidil in arterial hypertension and congestive heart failure.

Authors:  F H Messerli
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  Effects of atropine on human cardiac beta 1- and/or beta 2-adrenoceptor stimulation.

Authors:  Heike Bruck; Anke Ulrich; Stefan Gerlach; Joachim Radke; Otto-Erich Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-21       Impact factor: 3.000

Review 8.  Urapidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H D Langtry; G J Mammen; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

9.  Pharmacodynamics and pharmacokinetics of three different doses of urapidil infused in hypertensive patients.

Authors:  R Kirsten; K Nelson; J Neff; R Haerlin; V Steinijans; H W Radtke
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  The assessment of the beta-blocking activity of urapidil: a new method.

Authors:  M J Jamieson; S H Jackson; S S Patel; A M Shepherd; H Galbraith; W Stewart; P H Flanagan
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.